Search

UCB SA

Closed

SectorHealthcare

210.6 -0.28

Overview

Share price change

24h

Current

Min

210

Max

214.7

Key metrics

By Trading Economics

Income

28M

1.1B

Sales

16M

4.3B

P/E

Sector Avg

18.737

55.725

EPS

5.7

Dividend yield

0.7

Profit margin

26.019

Employees

9,000

EBITDA

587M

1.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.23% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.70%

2.25%

Market Stats

By TradingEconomics

Market Cap

-6.4B

40B

Previous open

210.88

Previous close

210.6

News Sentiment

By Acuity

67%

33%

282 / 339 Healthcare

UCB SA Chart

Past performance is not a reliable indicator of future results.

Related News

23 Sept 2026, 23:31 UTC

News
Social Media

Amazon.com Inc. is declining in after-market trading amid rising Treasury yields and geopolitical tensions, contributing to broader market downturns.

23 Sept 2026, 23:31 UTC

News

BWX Technologies Inc. received a BBB investment grade credit rating from Fitch Ratings, boosting after-market trading modestly higher.

23 Sept 2026, 23:31 UTC

Correlated Moves
News
Event

H.B. Fuller reported Q3 2026 net revenue of $938 million and adjusted EPS of $1.52, exceeding estimates, and traded higher in after-market hours.

23 Sept 2026, 23:26 UTC

Social Media
News

Robinhood Markets Inc. is trading slightly higher in after-market hours, bolstered by 13 revenue streams each generating over $100 million annually and positive growth forecasts.

23 Sept 2026, 23:25 UTC

News

Kraft Heinz Co is trading higher in after-market hours following RBC Capital Markets' "Outperform" rating and $32 price target, projecting 0.9% revenue growth by 2027.

23 Sept 2026, 23:21 UTC

News
Social Media

Meta Platforms Inc. is trading lower after-hours despite the launch of its Muse AI personal agent, which has garnered significant social media attention.

23 Sept 2026, 23:20 UTC

News

Goldman Sachs is selling Applied Systems, valued at up to $10 billion, as its stock moves higher in after-market trading amid active investment banking.

23 Sept 2026, 23:20 UTC

News

DoorDash Inc plans to pay $131.5 million to settle worker underpayment allegations, with its stock trading lower in after-market hours following the announcement.

23 Sept 2026, 23:16 UTC

News

Ethereum is trading lower, diverging from recent gains, amid rising U.S. crude oil inventories and strong economic data indicating robust private sector growth.

23 Sept 2026, 23:15 UTC

Social Media
News

Gossamer Bio Inc has submitted a New Drug Application for seralutinib targeting pulmonary arterial hypertension, with shares advancing in after-market trading.

23 Sept 2026, 23:15 UTC

News

Cooper Companies Inc's stock declines in after-market trading following a $30 million revenue miss in Q3, despite announcing a new global innovation hub in England.

23 Sept 2026, 23:15 UTC

News

AutoNation Inc announced a $1 million investment in cancer research grants, with its stock advancing modestly in after-market trading following the announcement.

23 Sept 2026, 23:11 UTC

Correlated Moves
News

The USD/SEK is advancing modestly as the U.S. dollar strengthens amid signals of potential Federal Reserve rate hikes to combat inflation.

23 Sept 2026, 23:06 UTC

News

UPS shares are slightly higher in after-market trading amid scrutiny over the diversion of sensitive F-35 parts to Hong Kong by the Chinese government.

23 Sept 2026, 23:06 UTC

Correlated Moves
News

Lockheed Martin's stock has gained in after-market hours following reports of the Chinese government seizing sensitive F-35 parts during shipment from Australia to the U.S.

23 Sept 2026, 23:06 UTC

Correlated Moves
News

Wells Fargo shares are modestly higher in after-market trading following the announcement of Chief Risk Officer Derek Flowers' upcoming retirement in mid-January.

23 Sept 2026, 23:06 UTC

Social Media
News

McDonald's is exploring menu growth opportunities for households using GLP-1 medications, with plans to reintroduce salads and grilled chicken items, gaining in after-market trading.

23 Sept 2026, 23:05 UTC

News

Lennar Corp. announced a quarterly dividend of $0.50 per share and reported increased stake from Berkshire Hathaway, with shares trading higher in after-market hours.

23 Sept 2026, 23:05 UTC

News

Altria Group Inc. is experiencing a decline in after-market trading amid potential regulatory changes for smoke-free nicotine products, raising concerns among public health advocates.

23 Sept 2026, 23:05 UTC

News

PepsiCo announced a significant order for 10k electric trucks through the ZET SCALE alliance, while its stock traded roughly flat in after-market hours.

23 Sept 2026, 23:05 UTC

News

Verizon grants $1 million to Liberty Science Center for AI initiative.

23 Sept 2026, 23:05 UTC

News

The USD/NOK is advancing modestly as U.S. crude oil inventories rose by 2.969 million barrels, raising supply concerns affecting the Norwegian krone.

23 Sept 2026, 23:05 UTC

News

General Mills Inc reports Q1 fiscal 2027 results with improved dollar sales and strong e-commerce growth, trading slightly higher in after-market hours.

23 Sept 2026, 23:01 UTC

News

Regenxbio Inc. has settled patent litigation with Sarepta Therapeutics, receiving $39 million, leading to a rise in after-market trading.

23 Sept 2026, 23:01 UTC

News

TransUnion shares are trading lower after CFO Todd Cello announced his planned departure at the end of 2026, despite reaffirmed financial guidance.

23 Sept 2026, 23:01 UTC

Correlated Moves
News

JPMorgan Chase & Co is involved in the sale of Applied Systems, valued at up to $10 billion, and is modestly higher in after-market trading.

23 Sept 2026, 23:01 UTC

News

AbbVie Inc. is down slightly in after-market trading, pulling back from an earlier session high, with a "Sell" rating and a price target of $191.

23 Sept 2026, 23:01 UTC

News
Social Media

MGM Resorts International's stock is sharply lower after Barry Diller withdrew his $18 billion acquisition bid, reaffirming the company's standalone commitment.

23 Sept 2026, 23:01 UTC

News

Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 and unveiled its LUNAR 2.0 platform, yet the stock is trading lower in after-market hours.

23 Sept 2026, 23:01 UTC

News

The USD/THB is advancing, reaching its highest cumulative return amid strong U.S. private sector growth, with the S&P Global Composite PMI rising to 58.4.

Peer Comparison

Price change

UCB SA Forecast

Price Target

By TipRanks

19.23% upside

12 Months Forecast

Average 94.86 EUR  19.23%

High 125 EUR

Low 74 EUR

Based on 7 Wall Street analysts offering 12 month price targets forUCB SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

4

Buy

1

Hold

2

Sell

Sentiment

By Acuity

282 / 339 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.